BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 32468420)

  • 1. Current status of immune checkpoint inhibitors for gastric cancer.
    Kono K; Nakajima S; Mimura K
    Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of immunotherapy for advanced gastric cancer.
    Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
    Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current management and biomarkers of immunotherapy in advanced gastric cancer.
    Chang X; Ge X; Zhang Y; Xue X
    Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
    Zhang Y; Yang Y; Chen Y; Lin W; Chen X; Liu J; Huang Y; Wang H; Teng L
    Front Immunol; 2022; 13():1060497. PubMed ID: 36505487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report.
    Zhang Z; Cheng S; Qi C; Zhang X; Peng Z; Shen L
    Ann Palliat Med; 2022 Feb; 11(2):818-826. PubMed ID: 34154337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.
    Zhang MJ; Chen DS; Li S; Chen L; Qi YX; Zhang CJ
    Invest New Drugs; 2021 Oct; 39(5):1436-1438. PubMed ID: 33913072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
    Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
    Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
    Cheng R; Li B; Wang H; Zeng Y
    Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Formica V; Morelli C; Patrikidou A; Murias C; Butt S; Nardecchia A; Lucchetti J; Renzi N; Shiu KK; Roselli M; Arkenau HT
    Target Oncol; 2020 Jun; 15(3):327-336. PubMed ID: 32449030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
    Kang BW; Chau I
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
    Li S; Gao J; Xu Q; Zhang X; Huang M; Dai X; Huang K; Liu L
    Front Immunol; 2021; 12():693314. PubMed ID: 34177954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.